Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement-Reference-Cited by-同舟云学术

Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement

Published:2014-01 Issue:1 Volume:83 Page:109-111
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Schwab Richard,Petak Istvan,Kollar Mihaly,Pinter Ferenc,Varkondi Edit,Kohanka Andrea,Barti-Juhasz Helga,Schönleber Julia,Brauswetter Diana,Kopper Laszlo,Urban Laszlo

Funder

OTKA-T046665NKFP_07_A2-NANODRUG OM-00080/2008

TECH_08_A2-STEMKILL OM-00107/2008

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference15 articles.

1. Crizotinib for ALK-rearranged non-small cell lung cancer: a new targeted therapy for a new target;Gandhi;Clin Cancer Res,2012

2. Crizotinib and testing for ALK;Shaw;J Natl Compr Canc Netw,2011

3. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification;Ou;J Thorac Oncol,2011

4. Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor;Chi;J Clin Oncol,2012

5. Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification;Okamoto;Mol Cancer Ther,2012

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Kinome-Wide Virtual Screening by Multi-Task Deep Learning;International Journal of Molecular Sciences;2024-02-22

2. MET in Non-Small-Cell Lung Cancer (NSCLC): Cross ‘a Long and Winding Road’ Looking for a Target;Cancers;2023-09-28

3. P40 and TTF‑1 double‑expressing non‑small cell lung cancer with EML4‑ALK and PIK3CA gene mutations: A case report and review of the literature;Oncology Letters;2022-12-20

4. Emerging Promise of Computational Techniques in Anti-Cancer Research: At a Glance;Bioengineering;2022-07-25

5. Case Report: Sequential Combination Targeted Therapy With Type I and II MET Inhibitors in a Metastatic EGFR-Mutated, MET-Amplified NSCLC Patient With Acquired MET Y1230H Mutation;Frontiers in Oncology;2021-12-02